Clinical Trial Update: Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2) [Phase 3]

View source ↗

Summary

Phase 3 PRIME2 evaluated dupilumab for prurigo nodularis inadequately controlled on topical therapies. The study status is completed with results posted in 2022…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Sanofi | Conditions: Neurodermatitis | Phase 3 | Status: COMPLETED | Results posted: 2022-09-28